Marsh & McLennan stock holds steady as Marsh Re rebrand and Q1 growth reshape the risk business

Marsh & McLennan stock is trading near USD 188 as investors weigh strong Q1 2026 revenue growth against a major rebrand of reinsurance arm Guy Carpenter to Marsh Re, reflecting the group’s push to streamline its risk and consulting franchise.

Marsh & McLennan (ISIN US5717481023) stock is quoted around USD 187.79 as of early trading on September 3, 2026, leaving the group valued close to its recent range between a one year low of USD 156.60 and a high of USD 207.82 according to market data compiled by MarketBeat.

Rebrand to Marsh Re puts the risk franchise in focus

A key strategic development for Marsh & McLennan this week is the decision to rebrand long standing reinsurance broker Guy Carpenter to Marsh Re, a change that took effect on September 1, 2026 and is aimed at building on the unit’s century long legacy within the wider Marsh & McLennan group, as reported by Asia Insurance Review.

According to Insurance News, the Marsh Re rebrand is described as a way to better align the reinsurance operation with the Marsh brand while maintaining the technical expertise and client relationships that Guy Carpenter has developed over decades, signaling that the group sees integrated branding as a lever for growth across its risk advisory platform.

Q1 2026 figures show solid revenue and earnings momentum

Against the backdrop of the Marsh Re rebrand, Marsh & McLennan’s most recent reported quarter underscores why the company is confident in its risk and consulting businesses. In Q1 2026, consolidated revenue increased 8% year over year to USD 7.6 billion, with underlying growth of 4% across the group according to an earnings call transcript published by Fortune.

Within that total, Marsh Risk & Insurance Services delivered 4% revenue growth in Q1 2026, while the consulting segment expanded by 5%, highlighting balanced progress across the company’s core engines and supporting investor confidence in the diversified model.

Marsh & McLennan also reported adjusted EPS of USD 3.29 for Q1 2026, an increase of 8% compared with the same period a year earlier, indicating that earnings grew slightly faster than revenue as operating leverage and cost discipline contributed to margin resilience.

Investor positioning and valuation context

The current share price around USD 187.79 places Marsh & McLennan roughly mid way between its one year low of USD 156.60 and its high of USD 207.82, suggesting that investors continue to ascribe a premium valuation but are waiting for the next set of quarterly figures and integration details around Marsh Re before pushing the stock back toward its peak.

Recent ownership disclosures compiled by MarketBeat show institutional investors adjusting their positions, with filings highlighting portfolio managers adding or trimming stakes as they factor Q1 growth and the brand consolidation into their long term view of Marsh & McLennan’s role in global risk management and consulting.

On the earnings outlook side, analyst consensus data referenced by MarketBeat points to expectations for full year EPS of about USD 10.44 for Marsh & McLennan, giving the market a framework for judging whether the combination of Marsh Re branding, Q1 momentum and upcoming quarters can sustain double digit earnings power.

Health benefits consulting as a growth driver

Beyond reinsurance and corporate risk broking, Marsh & McLennan’s health benefits consulting capabilities form another pillar of the business model. A September 2, 2026 release from Marsh outlines preliminary results of its 2026 National Survey of Employer Sponsored Health Plans, covering responses from more than 1,800 United States employers.

According to this Marsh survey, total health benefit cost per employee is expected to rise 8.2% on average in 2027, the highest projected increase since 2003, even after planned cost reduction measures, underscoring why employers are seeking more sophisticated advice on plan design, risk sharing and wellness programs.

For Marsh & McLennan, those expected cost pressures create additional demand for consulting and brokerage services in employer health benefits, positioning the firm’s advisory teams as key partners for companies which need to balance competitive employee offerings with sustainable long term cost trajectories.

Stock snapshot for investors

At a price of USD 187.79 as of September 3, 2026, Marsh & McLennan stock reflects the market’s assessment that the company’s diversified mix of Marsh Re, risk advisory, and health and retirement consulting can continue to deliver mid single digit revenue growth and high single digit earnings expansion while navigating rising benefit costs and evolving insurance market dynamics.

Marsh & McLennan stock fact box

• Company: Marsh & McLennan Companies, Inc.
• ISIN: US5717481023
• Ticker: MRSH
• Trading venue: NYSE
• Price (as of September 3, 2026): 187.79 USD
• Sector / Industry: Financial services / Insurance and consulting
• Index membership: S&P 500